Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04657068 · ClinicalTrials.gov registry record · Phase 1

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Artios Pharma.

Recruiting
Registry status
Phase 1
Development phase
442
Enrollment target
20
Study locations

NCT04657068 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Artios Pharma. The registered enrollment target is 442 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04657068, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Artios Pharma.

RECRUITING
Registry status
Phase 1
Development phase
442 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Conditions Studied

Ovarian Cancer Endometrial Cancer Advanced Cancer Metastatic Cancer Fallopian Tube Cancer Pancreatic Ductal Adenocarcinoma Metastatic Colorectal Cancer Primary Peritoneal Cancer Acinar Cell Carcinoma

Interventions

  • DRUG Gemcitabine
  • DRUG Irinotecan
  • DRUG ART0380

Study Locations (20)

Florida

  • Florida Cancer Specialists - Fort Myers
  • Mayo Clinic (Florida) - Jacksonville
  • Cancer Specialists of North Florida - Jacksonville
  • Florida Cancer Specialists - Orlando
  • Florida Cancer Specialists - Sarasota
  • Florida Cancer Specialists - West Palm Beach

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • Sansum Clinic - Santa Barbara
  • Providence Medical Foundation - Santa Rosa

Colorado

  • Rocky Mountain Cancer Center - Denver
  • Sarah Cannon Research Institute at HealthONE - Denver

Minnesota

  • Minnesota Oncology Hematology - Maple Grove
  • Mayo Clinic (Minnesota) - Rochester

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic (Arizona) - Scottsdale

Arkansas

  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute - Little Rock

Illinois

  • Hope and Healing Cancer Services - Hinsdale

Trial Details

FieldValue
Enrollment Target 442 participants
Start Date 2021-01-27
Est. Completion 2027-12
Phase Phase 1

Sponsor

Artios Pharma

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04657068

The ClinicalTrials.gov registry entry for NCT04657068 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (39% lower). The listed sponsor is Artios Pharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.

NCT04657068 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04657068 about?

NCT04657068 is a clinical study titled "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors". This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more...

What is the current status of trial NCT04657068?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 442 participants. The study started on 2021-01-27. Estimated completion is 2027-12.

What conditions does trial NCT04657068 study?

This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Advanced Cancer, Metastatic Cancer, Fallopian Tube Cancer.

What interventions are being tested in trial NCT04657068?

The interventions under investigation include: Gemcitabine (DRUG), Irinotecan (DRUG), ART0380 (DRUG).

Who is sponsoring clinical trial NCT04657068?

This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04657068 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.